Validation of a novel 3D culture platform for tnbc treatment selection
Active Grant Awarded Last action
- Award ID
- R01CA271682
- Recipient
-
The Methodist Hospital Research Institute UEI XJUCJAYJWYV1 Part of Universal Health Services, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,027,149
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 84% complete
- Place of performance
- Houston, TX 77030, USA
Award details come from USAspending.gov.
Description
- Abstract
- The goal of this academic [houston methodist research institute (HMRI) and MD anderson cancer center (MDACC)] and industrial (EMPIRI) collaborative project is to validate a novel, functional cancer diagnostic assay for clinical translation to improve and personalize the care of triple-negative breast cancer (TNBC) patients. The study will validate a novel 3D tumor tissue culture method (E-SLICES) invented by MPI kyuson YUN (HMRI) and licensed to EMPIRI, INC., a biotech startup CO-founded by DR. YUN and dave gallup (MPI). Together with DR. Naoto ueno (MPI, MDACC), a renowned physician-scientist specializing in TNBC research and patient care, the team will validate the predictive accuracy of E-SLICES for individual TNBC patient responses to recently approved chemoimmunotherapy for early TNBC patient care. The need for personalized medicine in oncology is widely accepted but translating this important concept into clinical practice has been challenging. Currently, the dominant platform for precision medicine utilizes genomics/sequencing-based assays to measure the expression and/or mutational profiles and then infer responses to targeted therapies; however, this approach benefits
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,198,662 | |
| Amendment | $0 | |
| Amendment | $583,104 | |
| Amendment | $601,157 | |
| Amendment | $0 | |
| Original award | $644,226 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| University Of Hawaii | $32,469 | |
| Empiri, Inc. | $182,210 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $159,861 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $111,155 | |
| University Of Hawaii | $66,871 | |
| The Univeristy Of Texas M.d. Anderson Cancer Center | $53,509 | |
| University Of Hawaii | $154,260 |
Quick answers
Who received award R01CA271682?
R01CA271682 was awarded to The Methodist Hospital Research Institute by National Cancer Institute (National Institutes of Health) on September 20, 2022.
How much is award R01CA271682 worth?
$3,027,149 has been obligated on R01CA271682.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award